Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Basilea Pharmaceutica's Revenue for the
six
months ended in Dec. 2025 was CHF128.4 Mil. Basilea Pharmaceutica's average Accounts Receivable for the
six
months ended in Dec. 2025 was CHF15.1 Mil.
Hence, Basilea Pharmaceutica's Receivables Turnover for the
six
months ended in Dec. 2025 was 8.53.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Basilea Pharmaceutica Receivables Turnover Related Terms
Basilea Pharmaceutica Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a Receivables Turnover of 8.53 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Basilea Pharmaceutica and its competitors. According to the industry distribution chart, Basilea Pharmaceutica ranks #90 out of 841 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Basilea Pharmaceutica's Receivables Turnover too high?
Basilea Pharmaceutica's current Receivables Turnover is 8.53. The Biotechnology industry median Receivables Turnover is 5.29. Basilea Pharmaceutica's value of 8.53 is 61.2% above this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #90 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #90 out of 841 companies for Receivables Turnover. This places Basilea Pharmaceutica in the top 11% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Basilea Pharmaceutica's value of 8.53 is 61.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Receivables Turnover of 8.53 is 61.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Receivables Turnover is 8.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.75, compared to a current price of CHF51.80 — trading 10.3% below its estimated fair value. The current Receivables Turnover is 8.53 and 61.2% above the Biotechnology industry median of 5.29. Basilea Pharmaceutica's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Receivables Turnover is 8.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF51.80 is trading 10.3% below its estimated GF Value™ of CHF57.75.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
Receivables Turnover: 8.53
GF Value™: CHF57.75 vs. price of CHF51.80 (10.3% below fair value)
Industry Position: 61.2% above the Biotechnology median (#90 of 841)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
58GF Score
Get the complete analysis for XSWX:BSLN
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
